Abcam agrees to be acquired by Danaher in $5.7B deal

Abcam Plc stock
ABCM,
+1.16%
was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp.
DHR,
+0.06%
for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday. Abcam said it expects to remain as a standalone operating company and brand within Danaher’s life sciences unit. The deal is expected to close in the middle of 2024. Danaher stock was down by 0.3% in premarket trades.